title: Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
abstract: We describe a 64-year-old man with decompensated hepatitis B virus (HBV)-related cirrhosis who became resistant to lamivudine. He was started on adefovir at 10 mg daily while continuing lamivudine therapy. Several months later, his liver function improved and subsequently his ascites disappeared. The serum HBV-DNA level became undetectable 11 months later. Twenty months after the start of additional treatment with adefovir, one hepatocellular carcinoma (HCC) was detected, and the patient underwent a successful hepatectomy. Our findings suggest that the addition of adefovir to ongoing lamivudine therapy is useful for improving liver function in patients with decompensated lamivudine-resistant HBV-related cirrhosis, allowing surgery for HCC.
authors.affiliation: Department of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Takamura
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ichida
authors.forename: Shogo
authors.initials: S
authors.lastname: Ohkoshi
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Tsubata
authors.forename: Akihiko
authors.initials: A
authors.lastname: Osaki
authors.forename: Tomoya
authors.initials: T
authors.lastname: Aoyagi
authors.forename: Minoru
authors.initials: M
authors.lastname: Nomoto
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Uehara
authors.forename: Haruo
authors.initials: H
authors.lastname: Terada
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Aoyagi
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D018450:Disease Progression; D024882:Drug Resistance, Viral; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D019259:Lamivudine / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D063065:Organophosphonates; D019259:Lamivudine; C053001:adefovir; D000225:Adenine